Impact of the Approval of Intravenous Recombinant Tissue Plasminogen Activator Therapy on the Processes of Acute Stroke Management in Japan | Zendy

Shoichiro Sato | Zendy; Toshiyuki Uehara | Zendy; Ḱazunori Toyoda | Zendy; Nobuyuki Yasui | Zendy; Takashi Hata | Zendy; Toshihiro Ueda | Zendy; Yasushi Okada | Zendy; Akihiro Toyota | Zendy; Yasuhiro Hasegawa | Zendy; Hiroaki Naritomi | Zendy; Kazuo Minematsu | Zendy

Open Access

Impact of the Approval of Intravenous Recombinant Tissue Plasminogen Activator Therapy on the Processes of Acute Stroke Management in Japan

Author(s) -

Shoichiro Sato,

Toshiyuki Uehara,

Ḱazunori Toyoda,

Nobuyuki Yasui,

Takashi Hata,

Toshihiro Ueda,

Yasushi Okada,

Akihiro Toyota,

Yasuhiro Hasegawa,

Hiroaki Naritomi,

Kazuo Minematsu

Publication year - 2008

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.108.524942

Subject(s) - medicine , stroke (engine) , tissue plasminogen activator , partial thromboplastin time , mechanical engineering , engineering , platelet

The Ministry of Health, Labor, and Welfare of Japan approved the use of recombinant tissue-type plasminogen activator (rt-PA) for the treatment of acute ischemic stroke in October 2005. The impact of the regulatory approval of rt-PA on the processes of acute stroke management was examined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research